Gilead Sciences agreed to acquire Ouro Medicines in a deal valued at about $2.17 billion, adding the company’s BCMAxCD3 T-cell engager gamgertamig (OM336) to Gilead’s autoimmune pipeline. The front-loaded transaction includes $1.675 billion in upfront cash and up to $500 million in milestone payments, with FDA Fast Track and Orphan Drug Designation already in place. Separately, the acquisition is structured to bring in Gilead’s existing partner Galapagos: the companies are in “advanced discussions” for Galapagos to absorb substantially all of Ouro’s operating assets and carry development through registrational studies expected to start in 2027. Gilead retains worldwide commercialization rights outside China, where Keymed Biosciences already holds a license. Biologically, gamgertamig is designed for rapid and deep B-cell depletion via a limited subcutaneous treatment course, positioning it as an immune-reset approach for autoimmune hemolytic anemia and immune thrombocytopenia—diseases in which early studies have been described as showing differentiated safety after a single treatment cycle.